Pulmonary embolism AI cleared

A Silicon Valley AI shop has been OK’d by the FDA to market software that automatically flags suspected pulmonary embolisms (PEs) and immediately notifies physicians.

San Mateo-based RapidAI announced the FDA go-ahead May 24, saying its Rapid PE Triage & Notification product speeds triaging of patients and alerting of care teams, in the process cutting time to treatment.

The newly cleared offering is designed to work with CT pulmonary angiogram (CTPA) images, optimally in conjunction with another RapidAI product, Rapid Workflow for PE.

The announcement quotes interventional cardiologist Jimmy Kerrigan, MD, of Ascension St. Thomas Heart in Tennessee.

Kerrigan suggests the new FDA clearance shows how “artificial intelligence will transform the way we triage and manage pulmonary embolism, a historically complicated process involving a diverse care team … I’m optimistic about its potential to optimize our care for patients and to hopefully improve patient outcomes.”

Find more pulmonary embolism content

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.